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by Dr J Tuomilehto, Dr J Salonen, Dr P Kuusisto, Dr J Virtamo, Dr V Manninen and Miss Marjatta Malkonen (North Karelia Project, University ofKuopio, Finland and Wihuri Research Institute, Helsinki, Finland) The population of the region of North Karelia in Eastern Finland has a very high morbidity and mortality from cardiovascular diseases, especially myocardial infarction and stroke (Puska 1974) . The levels of the main risk factors for cardiovascular diseases have been shown to be high . A preventive programme for control of cardiovascular diseases at the community level was launched in 1972, jointly with WHO, aimed at reducing the mortality of the population of North Karelia. The intervention is directed towards reduction of the levels of the main risk factors, i.e. serum cholesterol, smoking and hypertension, in the whole region (Puska 1973) .
Besides the intervention methods, which are directed towards the whole population, 'high risk persons' are specifically searched for, for example through a special screening programme for cardiovascular risk . The subjects are instructed in active individual intervention treatment of the observed diseases. At present, efforts have been focuised on the large-scale treatment of hypertension where the benefit of active intervention is most likely to lead to salutary results.
Advanced atherosclerosis at relatively young ages is, with hypertension, the other major medical peculiarity among the population of the area. The pathophysiological mechanisms are not fully worked out, but the high incidence of hypercholesterolkmia is almost certainly associated in some way.
Screening studies have revealed that 30% of middle-aged men have serum cholesterol levels above 7.5 mmol/l (Virtamo, unpublished The aim of this study was to introduce a controlled hypolipidmmic drug treatment for a cohort of subjects with primary hyperlipidemias living in the area of investigation. The aim was to observe the efficacy of the drug intervention, and at a later stage to compare the morbidity of atherosclerosis in this group with that of a matched control group receiving no treatment. Preliminary results from the period of drug treatment are given here.
Subjects and Methods
A total of 98 subjects with either serum cholesterol values above 8.0 mmol/l, or triglycerides above 2.0 mmol/l, or both, were included in the trial. The subjects were initially found to be hyperlipidkmic during a screening programme in the local community of Ilomantsi. Two-thirds of the subjects were male. Their ages varied between 23 and 60 years. Xanthomas were observed in . n Week 0 9.2 1.3 44 9.2 1.5 31 7.5 1.0 5 1.5 0.4 44 2.8 1.1 31 5.2. 1.4 5 Week 3 9.5 1.3 44 9.5 1.6 31 7.5 1.0 5 1.9 0.7 44 2.9 1.1 31 3.6 1.2 5 Week 6 9.6 1.5 44 9.7 1.6 31 7.5 0.7 5 2.0 0.6 44 3.3 1.4 31 4.1 1.5 5 n, number in Fredrickson type 13 %, retinopathy in 6 %, angina of effort in 34%, and peripheral ischaemia in 11 % of the subjects.
The subjects were first treated with placebo for six weeks. During this time, blood samples for baseline and general health screening were taken three times (Days 1, 21 and 42). Besides lipid parameters, the tests included ESR (Westergren), blood hemoglobin, hkmatocrit, white and red cell counts, serum-bilirubin, serum-alkaline phosphatase, SGPT and urinalysis.
All blood samples were taken after overnight fasting. Cholesterol was determined according to Pearson et al. (1953) , triglycerides according to Fletcher (1968) . Boehringer reagent kits were used for the determination of serum enzyme activities. Agarose gel-electrophoresis (modified from Noble 1968) was used in the classification of the hyperlipidmmias.
The subiects were instructed to continue with their normal day-to-day habits with regard to food and physical activity. However, no effort was made to monitor any changes that might have taken place.
The subjects were randomly allocated into two equal treatment groups (the gemfibrozil and clofibrate groups) after the placebo period. The initial dose of gemfibrozil was 800 mg daily, divided into two equal portions. If a satisfactory response was not obtained, the gemfibrozil was increased to 1200 mg daily. Clofibrate was given in a dose of 1500 mg daily, also in two equal portions.
The subjects visited the lipid clinic at fourweekly intervals. Blood samples were taken for the determination of serum cholesterol and triglycerides levels, ESR, leukocyte count and SGPT. A urinalysis was also done. During these visits inquiries were made into any side effects that might have appeared.
Results
The present analysis is of results generated from 80 subjects who received treatment for four months. There were 10 drop-outs unrelated to the drugs. The majority of these patients were unwilling to continue with the trial because of the time involved in the clinical visits. The area is sparsely populated, and patients had to travel up to 40 km from their homes to the place of investigation. Four patients in the gemfibrozil group dropped out because of unpleasant subjective side effects (abdominal discomfort and nausea), while one dropped out in the clofibrate group. The patient charactertistics in both groups under analysis are shown in Table 1 . Table 2 shows the main pretreatment values at 0, 3 and 6 weeks for the cohort of subjects on placebo.
There were 13 failures of response in the clofibrate group compared with 8 in the gemfibrozil group (a reduction of less than 10% in cholesterol and 10% in triglycerides). When these nonresponders are excluded, the mean reduction in the triglyceride level was 43 % in the gemfibrozil group and 36 % in the clofibrate group. The mean fasting serum triglyceride value fell from 2.8 mmol/l to 1.6 mmol/l in the gemfibrozil group and from 2.5 mmol/l to 1.6 mmol/l in the clofibrate group after 16 weeks of active treatment. The effect was in most cases clearly evident after the initial four-week check-up. The mean triglyceride values of both groups during the course of the trial are given in Table 3.   Table 3 Mean values (m) and standard deviations (s.d.) of fasting serum triglycerides during treatment in two treatment groups Table 4 Percentages of patients whose serum triglyceride levels were reduced by at least 10 % or by 20 % compared with the values after run-in period 9.4 1.6 9.7 1.7 Week 10 7.7 1.4 7.4 1.6 Week 14 7.9 1.5 7.4 1.3 Week 18 7.8 1.4 7.9 1.4 Week 22 7.6 1.5 7.5 1.2 Table 6 Percentages of patients whose serum cholesterol levels were reduced by at least 10 % or 20 % compared with the values after run-in period 
